Morphofunctional changes during the follow up of people living with obesity treated with semaglutide

Romo Remigio Roberto Carlos; Olivares Maria Garcia; Rovere Lara Dalla; Carmen Hardy; Cobos Cristina Herola; Jimenez Rocio Fernandez; Fernandezmmmmd Jose Abuin; Sachez Fracisco Hevilla; Jose Manuel

doi:10.1530/endoabs.110.EP933

EP933

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 110 EP933 | DOI: 10.1530/endoabs.110.EP933

ECEESPE2025 ePoster Presentations Metabolism, Nutrition and Obesity (164 abstracts)

Morphofunctional changes during the follow up of people living with obesity treated with semaglutide

Roberto Carlos Romo Remigio ¹ , María Garcia Olivares ¹ , Lara Dalla Rovere ¹ , Carmen Hardy ¹ , Cristina Herola Cobos ¹ , Rocio Fernández Jimenez ¹ , Jose Abuin Fernandezmmmmd ¹ , Fracisco Hevilla Sachez ¹ & Jose Manuel ¹

Author affiliations

¹QuironSalud Málaga Hospital, Endocrinology and Nutrition, Málaga, Spain

JOINT1251

Introduction: Obesity is a chronic metabolic disease that causes multiple complications in the medium and long term. GLP1 Analogues, including Wegovy (Semaglutide) 2.4mg, are the medical treatment that achieves significant and sustainable weight loss. Morphofunctional assessment (MFA) techniques, such as Bioimpedanciometry (BIA) with phase angle (PhA), Nutritional Ultrasound (NU) ® (which includes Rectus Femoris (RF) ultrasound and abdominal adiposity ultrasound) and handgrip strength (HGS) allow us to evaluate changes in body composition, beyond the weight.

Aim: To evaluate changes in body composition using MFA techniques in patients with Obesity undergoing treatment with Semaglutide.

Methods: Prospective observational study of patients living with obesity treated at the Obesity and Metabolism Unit of Quirónsalud Málaga Hospital. MFA data was collected using BIA-PhA (Akern) and ultrasound (Mindray® Z60) at the baseline visit and after 3 months of follow-up. Semaglutide doses were started and adjusted according to standard protocols and patients’ tolerance.

Results: 25 patients, of which 18 (72%) were women. The presence of comorbidity was evaluated using the AACE Scale: 2 patients had grade 0 (2.9%), 33 patients had grade 1 (47.1%), 35 patients had grade 2 (50%).

Table 1. The most significant data are presented in Table 1.
	Female		Male		Sig (p)
	Basal	3^rd month follow up	Basa	3^rd month follow up	SIG (P)
Weight (kg)	90,2±15,5	87,7±17,8	107±21	100±16,5	<0,001
Waist (cm)	106±13.6	105±17,2	121±14	112±9,1	<0,001
Hip (cm)	121±13,7	118±16,4	116±11,3	111±8,9	<0,001
Nº of Squats in 30 sec	19,9±5,9	22,3±5,11	20,7±4,6	23,7±2,25	<0,001
Average HGS	22,1±5,1	22,5±4,4	38±6,9	39,9±3,8	0,538
Phase-angle	5,9±0.65	5,8±0,45	6,4±0,79	6±0,79	0,048
Body Cell Mass (BCM)	27±3,61	26,1±3,5	38,3±5,44	36±3,2	<0,001
Adiposity free Mass (FFM)	50,3±5,64	49,3±5,62	69,2±9,27	67,7±7,98	<0,001
Adiposity Mass (FM)	39,9±11,6	38,4±13,1	38,7±12,7	32,6±10,6	<0,001
Rectus Femoris (RF) CSA	5±1	5±1,1	6,5±1,7	6,1±1	0,511
RF- Y axis	2±3,6	1,5±0,3	2,4±4,2	1,7±0,18	0,001
Lower limb – Subcutaneous adipose tissue (SAT)	2,14±0,74	1,28±0,45	2,10±0,7	1,12±0,35	0,001
Abdominal - SAT	3,18±1,52	2,56±1,45	2,72±0,82	1,8±0,85	0,001
Abdominal - SAT area	12,1±3,87	10,8±3,59	10,4±5,4	8,7±3,39	0,002
Visceral Adipose tissue Area	9±2,7	8,5±2,69	8,22±3,2	7,1±2,7	<0,001

Conclusions: Treatment with Semaglutide, along with a dietary program and physical activity recommendations, helps to reduce weight, mainly at the expense of the adipose component. Lower limb muscular area and function is preserved after 3 months of a weight loss program using Semaglutide.